Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,425.73
    -1,034.80 (-2.01%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

AstraZeneca sells British R&D site, to take $275 mln charge

Reuters - UK Focus

LONDON, March 12 (Reuters) - AstraZeneca (NYSE: AZN - news) has agreed to sell its Alderley Park research site in northern England to a public-private partnership group as it moves drug discovery to a new global centre in Cambridge (SES: E1:J91U.SI - news) .

The decision to close Alderley Park was a major blow for the northwest of the country, but the latest transaction has a silver lining as new owner Manchester Science Parks plans to keep the 400-acre site as a biotechnology campus.

The site lies with within the Cheshire parliamentary constituency of British Finance Minister George Osborne, who said on Wednesday he was delighted it would continue to play a role as a centre for the life sciences industry.

The sale follows a decision last March by AstraZeneca Chief Executive Pascal Soriot to move drug research and development to a new site in university city Cambridge in eastern England - a world-class centre for life sciences.

ADVERTISEMENT

Shifting research to Cambridge and creating a new global headquarters for the company in the city is the centrepiece of a major restructuring plan unveiled by Soriot last year, which also included a 10 percent cut in total staff numbers by 2016.

The overall cost of the restructuring was initially put at $2.3 billion, although the company revised this up to $2.5 billion when it presented full-year results last month.

Following the sale of the Alderley Park site, AstraZeneca (EUREX: AZNF.EX - news) said it would take pretax impairment charges of $275 million to non-core R&D expense in the first quarter of 2014 as part of the wider restructuring programme.

The financial terms of the sale were not disclosed.